PeerVoice Heart & Lung Video

PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Heart & Lung that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.

92 episodes

1mo ago latest

fortnightly cadence

English language

▶ Play latestRSS feed Website Science Health Fitness Medicine Education

https://c.peervoice.com/podcast/xml/pulmonology_video.xml

Episodes 93

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers
2d ago · 30:10
For the complete activity, including supporting material, please visit https://www.peervoice.com/EMH860. Presented by Giannis Mountzios, MD, PhD. Learning Objectives: Recall the results of pivotal clinical trials evaluating the role of Delta-like ligand 3 (DLL3)-targeted T-cell engagers in the treatment of extensive-stage small-cell lung cancer (ES-SCLC); Identify patients presenting with progressive ES-SCLC who may benefit from treatment with a DLL3-targeted therapy; Provide DLL3-targeted therapy appropriately, considering factors such as timing of dosing and recommended premedication and ste
Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management
1mo ago · 16:39
For the complete activity, including supporting material, please visit https://www.peervoice.com/VUR860. Presented by Kausik Ray, MD, MPhil (Cantab), FMedSci. Learning Objectives: Discuss the rationale and importance of earlier recognition of patients with and at high risk of atherosclerotic cardiovascular disease (ASCVD); Identify key features associated with high-risk ASCVD; Apply practical strategies for achieving effective lipid control in individuals at high risk of ASCVD.
Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health
2mo ago · 1:17:14
For the complete activity, including supporting material, please visit https://www.peervoice.com/VAC860. Presented by Carel le Roux, MBChB, MSc, PhD; Biykem Bozkurt, MD, PhD; Domenica M. Rubino, MD; and Michael Donnelly-Boylen, MS. Learning Objectives: Describe the pathophysiologic relationship between obesity, metabolic dysfunction, and end-organ injury across cardiovascular, renal, and metabolic disease; Evaluate key clinical and psychosocial factors that influence multidisciplinary management decisions for patients with obesity and related cardiovascular-renal-metabolic disease; Apply evide
Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional
3mo ago · 1:20:09
For the complete activity, including supporting material, please visit https://www.peervoice.com/ZRT860. Presented by Anjali Tiku Owens, MD; Andrew Willeford, PharmD, PhD, BCCP; and Rachel Lavelle, PharmD, BCCP Learning Objectives: Differentiate between obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM) based on their pathophysiology and current guideline-directed management strategies; Evaluate the efficacy and safety of cardiac myosin inhibition as monotherapy or first-line therapy for oHCM in comparison to beta-blockade; Compare available cardiac myosin inhibitors (
Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition
4mo ago · 36:53
For the complete activity, including supporting material, please visit https://www.peervoice.com/FBM860. Presented by Xin Cheng, MD, PhD; Ashkan Shoamanesh, MD, FRCPC; and Jeffrey Weitz, MD, OC, FRCPC. Learning Objectives: Explain the rationale and potential role for Factor XIa inhibition in secondary prevention of non-cardioembolic ischaemic stroke (NCIS) or high-risk transient ischaemic attack (TIA); Recall the trial design, methodology, and inclusion criteria for key phase 3 trials of Factor XIa inhibitors in secondary stroke prevention (SSP) of NCIS or high-risk TIA; Evaluate clinical outc
Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
5mo ago · 40:01
For the complete activity, including supporting material, please visit https://www.peervoice.com/KBA860. Presented by Jonathan W. Goldman, MD and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guideline recommendations for the use of immunotherapy in small cell lung cancer (SCLC); Evaluate the rationale, evidence, and implications of emerging strategies for treatment of extensive-stage (ES)-SCLC, including use of combination therapy in the maintenance phase of first-line treatment; Identify relevant patient and disease-specific considerations that may gu
Louise Moist, MD, MSc, CCPE / Peter J. Lin, MD, CCFP - Managing CKD With SGLT2 Inhibitors in Primary Care: Applying New Evidence Into Clinical Practice
6mo ago · 14:00
For the complete activity, including supporting material, please visit https://www.peervoice.com/UBG860. Presented by Louise Moist, MD, MSc, CCPE; Peter J. Lin, MD, CCFP; and James Woijoo Kim, MBBCh, PgDip, MScCH, CPC(HC). Learning Objectives: Recognize current guideline recommendations on the use of SGLT2 inhibitors for the management of CKD; Evaluate the latest evidence on SGLT2 inhibitors in patients with CKD with or without T2D; Outline evidence-based, individualized strategies to optimize the use of SGLT2 inhibitors in patients with cardio-renal-metabolic conditions.
Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies
6mo ago · 21:51
For the complete activity, including supporting material, please visit https://www.peervoice.com/XZR860. Presented by Melanie J. Davies, CBE, MBChB, MD, FMedSci and Linong Ji, MD. Learning Objectives: Describe the importance of optimal cost-effective approaches to the pharmacologic management of type 2 diabetes mellitus (T2DM); Evaluate the role of established medications for T2DM for avoiding potential cardiorenal complications in patients with T2DM; Propose practical approaches to address cost and clinical effectiveness for patients with T2DM.
Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management
7mo ago · 29:06
Visit https://www.peervoice.com/URW860 to view the entire programme with slides. After completing “Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management”, participants will be able to: Identify patients with persistent chylomicronemia, including familial chylomicronemia syndrome (FCS), based on clinical presentation and recommended diagnostic criteria; Recall the mechanisms of and evidence for novel treatments for management of FCS; and Apply comprehensive, patient-centered approaches to th
Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities
8mo ago · 9:49
Visit https://www.peervoice.com/NNA860 to view the entire programme with slides. After completing “Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities”, participants will be able to: Evaluate the impact of APOC-III—directed therapies on clinical and patient-centered outcomes in familial chylomicronemia syndrome (FCS); and Differentiate between APOC-III—directed therapies approved for the management of FCS, including their molecular modalities, frequency of administration, contraindications to use, and adverse-event
John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes
8mo ago · 30:19
Visit https://www.peervoice.com/FTR860 to view the entire programme with slides. After completing “John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes”, participants will be able to: Summarize the complications, burden, and unmet needs associated with the diagnosis and management of hypercortisolism; Describe the mechanistic rationale associated with new and emerging therapies in hypercortisolism; Recall safety and efficacy data rela
Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?
8mo ago · 29:03
Visit https://www.peervoice.com/EPK860 to view the entire programme with slides. After completing “Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?”, participants will be able to: Evaluate the strengths and limitations of multimodality cardiac imaging within the evolving diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM); Assess the role and applications for multimodality cardiac imaging in monitoring treatment
David Cherney, MD, PhD / Abhinav Sharma, MD, PhD - Optimizing Cardio-Kidney Protection in Patients With T2D and CKD: Expert Insights on the Evolving Role of GLP-1 RAs
8mo ago · 23:58
Visit https://www.peervoice.com/HPJ860 to view the entire programme with slides. After completing “David Cherney, MD, PhD / Abhinav Sharma, MD, PhD - Optimizing Cardio-Kidney Protection in Patients With T2D and CKD: Expert Insights on the Evolving Role of GLP-1 RAs”, participants will be able to: Examine the pathogenic mechanisms underlying chronic kidney disease (CKD) and type 2 diabetes (T2D), and their relevance to the foundational pillars of cardio-kidney protection; Discuss the latest clinical evidence on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing cardio-kidney pro
Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM
9mo ago · 18:31
Visit https://www.peervoice.com/BJJ860 to view the entire programme with slides. After completing “Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM”, participants will be able to: Identify the impact of disease-modifying therapies on accepted markers of transthyretin amyloid cardiomyopathy (ATTR-CM) disease severity, including NT-proBNP, 6MWD, and NAC stage in phase 3 trial populations; and Evaluate recently presented outcomes from post-hoc analyses and open-label extensions of phase 3 trials in ATTR-CM in the context of pre
Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves
9mo ago · 38:34
Visit https://www.peervoice.com/FMW860 to view the entire programme with slides. After completing “Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves”, participants will be able to: Assess available data which may be applied to guide treatment decision-making within the evolving treatment landscape of transthyretin amyloid cardiomyopathy (ATTR-CM); Differentiate between TTR stabilisers based on existing evidence in ATTR-CM; and Apply current evidence related to the use of combination the
Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care
10mo ago · 48:36
Visit https://www.peervoice.com/XSX860 to view the entire programme with slides. After completing “Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care”, participants will be able to: Apply current guideline recommendations for timely testing and screening for alpha-1 antitrypsin deficiency (AATD) to facilitate early diagnosis and interventions; Identify best practices and practical strategies for the collaborative monitoring and management of patients with AATD; and Assess the phase 3 landscape of investigational therapi
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
11mo ago · 1:01:14
Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish betwe
Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence
1y ago · 9:54
Visit https://www.peervoice.com/STJ860 to view the entire programme with slides. After completing “Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence”, participants will be able to: Improved knowledge of current efficacy data from clinical trials of novel treatments for familial chylomicronemia syndrome (FCS); and Improved knowledge of the safety profiles of emerging treatments for FCS, based on clinical trial outcomes.
Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
1y ago · 35:55
Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: Recognise the rationale behind TROP2 as a therapeutic target in NSCLC; Recall the results of clinical trials assessing the safety and efficacy of TROP2-directed therapy across different types of NSCLC, including non-oncogene-addicted, EGFR-mutant and ALK-rearranged NSCLC; and Assess the clinical relevance of subgroup analyses evaluating the effect of TROP2-dir
Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer
1y ago · 30:01
Visit https://www.peervoice.com/GWG860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer”, participants will be able to: Recognise the perspectives and concerns of patients with locally advanced, unresectable EGFR-mutated NSCLC in evaluating treatment decisions; Apply practical approaches to facilitate patient understanding of the rationale, implications, and benefits of curative intent treatment strategies in the management of locally a
Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials
1y ago · 31:29
Visit https://www.peervoice.com/MGY860 to view the entire programme with slides. After completing “Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials”, participants will be able to: Compare the study designs and endpoints of pivotal phase 3 clinical trials in transthyretin amyloid cardiomyopathy (ATTR-CM); Identify the differences in baseline characteristics of study populations in key phase 3 trials in ATTR-CM and their impact on study outcomes; and Eva
Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?
1y ago · 18:09
Visit https://www.peervoice.com/VBS860 to view the entire programme with slides. After completing “Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?”, participants will be able to: Identify strategies to improve communication between people living with HIV (PWLH) and healthcare providers (HCPs), reduce HCP stigma, and build positive perceptions of health management by non-HIV specialist HCPs; and Propose key practical preventative steps for HIV-associated comorbidities.
Yves Robitaille, MD, CSPQ, DABOM - Cardiovascular Risk Management in Patients Living With Obesity: Applying the Latest Evidence to Practice
1y ago · 21:41
Visit https://www.peervoice.com/RUF860 to view the entire programme with slides. After completing “Yves Robitaille, MD, CSPQ, DABOM - Cardiovascular Risk Management in Patients Living With Obesity: Applying the Latest Evidence to Practice”, participants will be able to: Describe the association between obesity and the risk of cardiovascular disease (CVD); Evaluate the latest clinical evidence of various therapeutic options, including GLP-1 receptor agonists, in patients living with obesity and CVD; Discuss comprehensive treatment strategies to improve cardiovascular risk in patients living wit
Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care
1y ago · 36:14
Visit https://www.peervoice.com/CNZ860 to view the entire programme with slides. After completing “Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care”, participants will be able to: Recognise the role, strengths, and limitations of real-world evidence in guiding decision-making related to stroke prevention in patients with atrial fibrillation (AF); Evaluate available real-world data studies related to the use of oral anticoagulants for stroke prevention in AF, including in special p
Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care
1y ago · 8:51
Visit https://www.peervoice.com/JPM860 to view the entire programme with slides. After completing “Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care”, participants will be able to: Evaluate the latest clinical evidence of RNA-targeted therapies for hereditary transthyretin amyloidosis with polyneuropathy (hATTR PN); Formulate individualized treatment plans based on disease and patient factors; and Summarize current and emerging data for transthyretin amyloid cardiomyopathy (ATTR CM).

Episodes

Reading the feed…

Also on peervoice.com

More Science shows

Arizona Science

azpm.org

510 episodes · 9d ago

WiTcast

witcastthailand.com

357 episodes · 8d ago

Evrim Ağacı ile Bilime Dair Her Şey!

evrimagaci.org

557 episodes · 8d ago

A Moment of Science

prxu.org

1,000 episodes · 9d ago

Groks Science Radio Show and Podcast

ocf.berkeley.edu

1,000 episodes · 11d ago

Ask the Naked Scientists

thenakedscientists.com

802 episodes · 9d ago

PeerVoice Heart & Lung Video

Episodes 93

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Louise Moist, MD, MSc, CCPE / Peter J. Lin, MD, CCFP - Managing CKD With SGLT2 Inhibitors in Primary Care: Applying New Evidence Into Clinical Practice

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

David Cherney, MD, PhD / Abhinav Sharma, MD, PhD - Optimizing Cardio-Kidney Protection in Patients With T2D and CKD: Expert Insights on the Evolving Role of GLP-1 RAs

Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?

Yves Robitaille, MD, CSPQ, DABOM - Cardiovascular Risk Management in Patients Living With Obesity: Applying the Latest Evidence to Practice

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care

Episodes

Also on peervoice.com

PeerVoice Internal Medicine Video

PeerVoice Internal Medicine Audio

PeerVoice Clinical Pharmacology Video

PeerVoice Oncology & Haematology Video

PeerVoice Clinical Pharmacology Audio

PeerVoice Oncology & Haematology Audio

More Science shows

Arizona Science

WiTcast

Evrim Ağacı ile Bilime Dair Her Şey!

A Moment of Science

Groks Science Radio Show and Podcast

Ask the Naked Scientists

Episodes 93

Giannis Mountzios, MD, PhD - Preparing to Turn Potential Into Progress in ES-SCLC: The Practicalities of DLL3-Targeted T-Cell Engagers

Kausik Ray, MD, MPhil (Cantab), FMedSci - Altering the Disease Trajectory in Patients With and at High Risk of Atherosclerotic Cardiovascular Disease: Ensuring Best Practices for Identification and Management

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Louise Moist, MD, MSc, CCPE / Peter J. Lin, MD, CCFP - Managing CKD With SGLT2 Inhibitors in Primary Care: Applying New Evidence Into Clinical Practice

Melanie J. Davies, CBE, MBChB, MD, FMedSci / Linong Ji, MD - Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Established Therapies

Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management

Ira Goldberg, MD - The Expanding Treatment Landscape for Familial Chylomicronemia Syndrome: Exploring New Options and Opportunities

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?

David Cherney, MD, PhD / Abhinav Sharma, MD, PhD - Optimizing Cardio-Kidney Protection in Patients With T2D and CKD: Expert Insights on the Evolving Role of GLP-1 RAs

Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM

Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer

Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?

Yves Robitaille, MD, CSPQ, DABOM - Cardiovascular Risk Management in Patients Living With Obesity: Applying the Latest Evidence to Practice

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care